title: Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychologic issues, and adherence.
abstract: BACKGROUND
  Efavirenz has been associated with neuropsychiatric disorders, although little is known about its long-term toxicity.
  
  
  OBJECTIVE
  To assess neuropsychiatric disorders and their relation to efavirenz plasma levels as well as quality of life, psychologic status, and adherence in HIV-infected patients on long-term efavirenz-based antiretroviral therapy.
  
  
  METHODS
  Cross-sectional study comparing 60 patients on an efavirenz-based approach (EFV group) and 60 patients on a protease inhibitor-containing regimen (PI group) for at least 1 year. Adverse events, efavirenz plasma levels, quality of life, psychologic status, and adherence were assessed.
  
  
  RESULTS
  The mean time on treatment was 91.1 +/- 39.5 weeks in the EFV group and 119.9 +/- 67.4 weeks in the PI group. Mild dizziness, sadness, mood changes, irritability, lightheadedness, nervousness, impaired concentration, abnormal dreams, and somnolence were reported more frequently in the EFV group than in the PI group (P < 0.05). Forty-nine of 60 patients presented with therapeutic efavirenz plasma levels (range: 1.0-4.0 mg/L). Efavirenz plasma levels were similar in subjects with and without neuropsychiatric disorders. No significant differences were found between the EFV group and the PI group regarding quality of life and psychologic status. Sixty percent of patients in the EFV group and 55% in the PI group reported adherence >/=95%.
  
  
  CONCLUSIONS
  Mild and clinically tolerable neuropsychiatric disorders may persist in patients after a mean of 2 years using an efavirenz-based approach. Quality of life and psychologic status remained good in both study groups. Interventions to enhance long-term adherence should be applied in clinical practice.
authors.affiliation: Lluita contra la SIDA Foundation, HIV Unit-Germans Trias i Pujol Hospital, Autonomous University of Barcelona, Barcelona, Spain. cfumaz@ns.hugtip.scs.es
authors.forename: Carmina R
authors.initials: CR
authors.lastname: Fumaz
authors.forename: Jose A
authors.initials: JA
authors.lastname: Muñoz-Moreno
authors.forename: José
authors.initials: J
authors.lastname: Moltó
authors.forename: Eugènia
authors.initials: E
authors.lastname: Negredo
authors.forename: Maria José
authors.initials: MJ
authors.lastname: Ferrer
authors.forename: Guillem
authors.initials: G
authors.lastname: Sirera
authors.forename: Núria
authors.initials: N
authors.lastname: Pérez-Alvarez
authors.forename: Guadalupe
authors.initials: G
authors.lastname: Gómez
authors.forename: David
authors.initials: D
authors.lastname: Burger
authors.forename: Bonaventura
authors.initials: B
authors.lastname: Clotet
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy* / Q000523:psychology* / Q000635:transmission; D000328:Adult; D000480:Alkynes; D019380:Anti-HIV Agents / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D048588:Benzoxazines; D002493:Central Nervous System Diseases / Q000139:chemically induced / Q000523:psychology*; D003072:Cognition Disorders / Q000139:chemically induced*; D003521:Cyclopropanes; D004651:Employment; D005260:Female; D006801:Humans; D008297:Male; D019964:Mood Disorders / Q000139:chemically induced*; D010078:Oxazines / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D010349:Patient Compliance; D011788:Quality of Life; D012189:Retrospective Studies; D012309:Risk-Taking; D011795:Surveys and Questionnaires
chemical_list: D000480:Alkynes; D019380:Anti-HIV Agents; D048588:Benzoxazines; D003521:Cyclopropanes; D010078:Oxazines; C098320:efavirenz